Insulin makers and PBMs are being sued by more states, local governments

Lawsuits allege that the companies artificially drove up the cost of insulin, making the medication unaffordable for countless residents.

November 28, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs The lawsuits claim companies artificially drove up the cost of insulin, making the diabetes medicine unaffordable for countless residents. By Ed Silverman and John Wilkerson STAT+ | FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma Reported cases of CAR-T-caused cancer are rare but serious, the agency says, adding that benefits still outweigh potential risks. By Angus Chen and Matthew Herper and Jason Mast STAT+ | Biden invokes Defense Production Act to stem drug shortages Biden's plan to stem drug shortages involves using the Defense Production Act, a Cold War-era law, to bring drug making back to the U.S. By John Wilkerson Adobe The push to get estrogen FDA-approved for gender-affirming care A nonprofit group is pursuing a clinical trial with the goal of FDA approval for estrogen as a gender-affirming treatment for trans patients. By Theresa Gaffney STAT+ | Mayo Clinic to spend $5 billion on tech-heavy redesign of its Minnesota campus Mayo Clinic plans to reinvent its flagship medical campus in Minnesota, infusing digital technologies into several new buildings. By Casey Ross Opinion: Manufacturers need to be more open about a dangerous Alzheimer's drug side effect Alzheimer's patients deserve to know more about brain swelling and bleeding from drugs such as lecanemab, aducanumab and donanemab. By Madhav Thambisetty Adobe How to spot when drug companies spin clinical trial results STAT has released the update of its Guide to Interpreting Clinical Trial Results, to help consumers of company readouts navigate the process. By STAT Staff STAT+ | Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it's not enough Patient advocates want Vertex to drop patent claims and implement a global pricing model reflecting R&D and production costs. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser